Shawn Cazzell, DPM
Podiatrist · Fresno, CANPI 1629392568
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,937 of the $19,009 with a category attached, or 99.6%. 5 manufacturers reported payments, led by Royal Biologics, Inc. at 55.4% of the total. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 5 payments — averaging $3801.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Royal Biologics, Inc.$11K
- Biotissue Holdings Inc.$8K
- Medtronic$900
- Amnio Technology, LLC$45
- Mallinckrodt Enterprises LLC$27
Across 82 payments — averaging $10,933 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$224K
- Organogenesis Inc.$191K
- Integra Lifesciences Corporation$123K
- Ipsen Innovation$102K
- Acell, Inc.$88K
- Globus Medical$67K
- plus $102K from 4 others
What the payments were for
- Consulting fees$18,937100%
- Food & beverage$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Royal Biologics, Inc. | 1 | $10,537 |
| Biotissue Holdings Inc. | 1 | $7,500 |
| Medtronic | 1 | $900 |
| Amnio Technology, LLC | 1 | $45 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fibrinet$10,537
- INTELLIS ADAPTIVESTIM$900
How this compares
$19,009 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $214 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Fresno
- Emmy OjiFresno$29K
- Robert BuckenbergerFresno$21K
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.